BJH - 2024, issue Special, may 2024
J. Collins PhD, T. Feys MBA, MSc
Chemoimmunotherapy (CIT) has been the long-standing cornerstone of the first line treatment for patients with chronic lymphocytic leukaemia (CLL). More recently, however, continuous treatment with Bruton’s tyrosine kinase inhibitors (BTKis) emerged as a new standard of care frontline treatment for the majority of CLL patients. However, the continuous nature of this treatment modality is associated with a considerable treatment burden, long-term toxicity and potential clonal selection. Therefore, research efforts have focused on the development of new, time-limited and chemotherapy-free first line treatment regimens for patients with CLL.1 In this mini review, the main clinical trial results with these different fixed-duration regimens are summarised.
Read moreBJH - 2024, issue Special, may 2024
A. Enguita PhD, T. Feys MBA, MSc
Bruton tyrosine kinase inhibitors (BTKis) have revolutionised the treatment landscape for patients with chronic lymphocytic leukaemia (CLL) and several non-Hodgkin lymphoma (NHL) subtypes, including mantle cell lymphoma (MCL). Despite the efficacy of covalent BTKis (cBTKis), the development of resistance mutations leads to poor outcomes in patients who relapse after a cBTKi-based therapy. Non-covalent BTKis (ncBTKis), such as pirtobrutinib, have a different mode of action than cBTKis allowing them to overcome this acquired resistance. In recent years, several clinical trials have yielded promising results with pirtobrutinib and other ncBTKis in patients progressing on a cBTKi. This article zooms in on the unmet clinical needs of cBTKi-resistant patients, exploring pivotal findings from clinical trials assessing pirtobrutinib in this context, alongside other prospective strategies.
Read moreBJH - 2024, issue Special, may 2024
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In recent years, the treatment landscape of patients with relapsed or refractory diffuse-large B-cell lymphoma (R/R DLBCL) has changed dramatically. This mini review will briefly discuss the clinical trial data that were obtained with these different options.
Read moreBJH - 2024, issue Special, may 2024
J. Collins PhD, T. Feys MBA, MSc
Follicular lymphoma (FL) is the most common B-cell non-Hodgkin lymphoma (NHL) and typically follows an indolent disease course. While some patients do not require treatment until certain criteria are met, others may progress to an aggressive lymphoma phenotype requiring a different treatment approach. The current standard initial treatment for FL consists of chemo-immunotherapy in which cytotoxic chemotherapy is combined with an anti-CD20 antibody. In general, this treatment strategy is highly effective, significantly delaying disease progression and postponing the need for additional therapy for many years. However, a proportion of patients may experience chemotherapy-related toxicities, while others prove to be chemotherapy-refractory. For these patients, an effective chemotherapy-free treatment approach is sought. This article provides a concise overview of the mechanisms of action of potential targeted therapies for FL and briefly discusses the available clinical trial data.1
Read moreBJH - 2023, issue Recent highlights in Acute Leukemia, october 2023
T. Feys MBA, MSc
Over the last decade, major advances in the molecular profiling of acute myeloid leukemia (AML) led to a deeper understanding of its pathobiology and revealed potential therapeutic vulnerabilities. As a result, the classification of AML subtypes has evolved from a morphologic to a molecular and genetic basis. After years of stagnation, we have recently witnessed a rapid expansion of the therapeutic armamentarium for AML. Apart from the use of low-intensity induction therapy with hypomethylating agents and venetoclax in patients who are ineligible for intensive chemotherapy, this includes the introduction of targeted agents for the treatment of AML patients harboring specific driver mutations.
Read moreBJH - 2023, issue Recent highlights in Acute Leukemia, october 2023
J. Blokken PhD, PharmD
Based on the results of the phase III Study 301, Vyxeos Liposomal was approved in Europe in 2018 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukaemia (AML) and AML with myelodysplasia-related changes. Since then, various real-world studies have assessed the safety and efficacy of this drug in routine clinical practice. The real-world evidence that was obtained not only supports the results from the clinical trial but also addresses an important data gap in terms of the achievement of minimal residual disease (MRD) negativity. Below we summarize the real-world experience with Vyxeos Liposomal in patients with high-risk AML.
Read moreBJH - 2023, issue Recent highlights in Acute Leukemia, october 2023
T. Feys MBA, MSc
About half of the adult patients with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve a molecular complete remission or who subsequently relapse cannot be cured with the current chemotherapy or targeted agents. In recent years, however, we have witnessed the emergence of different immune-based therapies in this setting. This includes monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibodydrug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs).
Read more
Top
